KDR and neoplasm: Anlotinib inhibits various angiogenic signaling pathways, including those mediated by VEGF and fibroblast growth factor (FGF), which are pivotal in tumor growth and metastasis.[48] Crucially, the inhibition of VEGFR-mediated signaling not only deprives tumors of essential blood supply via antiangiogenesis but also promotes the “normalization” of the tortuous and leaky tumor vasculature.[36] This vascular normalization improves tissue perfusion, alleviates intratumoral hypoxia – a potent immunosuppressive stimulus – and potentially reduces the recruitment of inhibitory immune cells.